http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationshttp://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations33000000Amphastar Pharmaceuticals, Inc.--12-31false00012971842023-03-31Q100000001297184us-gaap:SalesReturnsAndAllowancesMember2023-01-012023-03-310001297184us-gaap:SalesReturnsAndAllowancesMember2022-01-012022-03-310001297184us-gaap:SalesReturnsAndAllowancesMember2023-03-310001297184us-gaap:SalesReturnsAndAllowancesMember2022-12-310001297184us-gaap:SalesReturnsAndAllowancesMember2022-03-310001297184us-gaap:SalesReturnsAndAllowancesMember2021-12-310001297184us-gaap:TreasuryStockMember2023-01-012023-03-310001297184amph:November2014ShareRepurchasePlanMember2023-01-012023-03-310001297184amph:November2014ShareRepurchasePlanMember2022-01-012022-03-310001297184amph:November2014ShareRepurchasePlanMember2022-11-030001297184us-gaap:TreasuryStockMember2022-01-012022-03-310001297184us-gaap:CommonStockMember2023-01-012023-03-310001297184us-gaap:CommonStockMember2022-01-012022-03-310001297184us-gaap:RetainedEarningsMember2023-03-310001297184us-gaap:AdditionalPaidInCapitalMember2023-03-310001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001297184us-gaap:RetainedEarningsMember2022-12-310001297184us-gaap:AdditionalPaidInCapitalMember2022-12-310001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001297184us-gaap:RetainedEarningsMember2022-03-310001297184us-gaap:AdditionalPaidInCapitalMember2022-03-310001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001297184us-gaap:RetainedEarningsMember2021-12-310001297184us-gaap:AdditionalPaidInCapitalMember2021-12-310001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001297184amph:EmployeeStockPurchasePlan2014Member2023-03-310001297184amph:The2015EquityIncentivePlanMember2023-03-310001297184amph:The2015EquityIncentivePlanMember2023-01-012023-01-310001297184us-gaap:RestrictedStockUnitsRSUMember2022-12-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:PhytonadioneMember2023-01-012023-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:OtherFinishedPharmaceuticalProductsMember2023-01-012023-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:NaloxoneMember2023-01-012023-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:LidocaineMember2023-01-012023-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:GlucagonMember2023-01-012023-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:EpinephrineMember2023-01-012023-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:EnoxaparinMember2023-01-012023-03-310001297184amph:AnpMemberamph:ResearchAndDevelopmentServicesMember2023-01-012023-03-310001297184country:US2023-01-012023-03-310001297184country:FR2023-01-012023-03-310001297184country:CN2023-01-012023-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:PhytonadioneMember2022-01-012022-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:OtherFinishedPharmaceuticalProductsMember2022-01-012022-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:NaloxoneMember2022-01-012022-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:LidocaineMember2022-01-012022-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:GlucagonMember2022-01-012022-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:EpinephrineMember2022-01-012022-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:EnoxaparinMember2022-01-012022-03-310001297184amph:AnpMemberamph:ResearchAndDevelopmentServicesMember2022-01-012022-03-310001297184country:US2022-01-012022-03-310001297184country:FR2022-01-012022-03-310001297184country:CN2022-01-012022-03-310001297184amph:AnpMemberamph:NanjingHanxinPharmaceuticalTechnologyCoLtdMember2023-01-012023-03-310001297184amph:NanjingLetopMedicalTechnologyCo.Ltd.Member2023-01-012023-03-310001297184amph:NanjingLetopMedicalTechnologyCo.Ltd.Member2023-03-310001297184amph:NanjingHanxinPharmaceuticalTechnologyCoLtdMember2023-03-310001297184amph:AnpMemberamph:NanjingHanxinPharmaceuticalTechnologyCoLtdMember2023-03-310001297184amph:NanjingHanxinPharmaceuticalTechnologyCoLtdMember2023-03-012023-03-310001297184amph:NanjingLetopMedicalTechnologyCo.Ltd.Member2022-11-012022-11-300001297184amph:NanjingHanxinPharmaceuticalTechnologyCoLtdMember2022-07-012022-07-310001297184us-gaap:MachineryAndEquipmentMember2023-03-310001297184us-gaap:LeaseholdImprovementsMember2023-03-310001297184us-gaap:LandMember2023-03-310001297184us-gaap:ConstructionInProgressMember2023-03-310001297184us-gaap:BuildingMember2023-03-310001297184amph:FurnitureFixturesAndVehiclesMember2023-03-310001297184us-gaap:MachineryAndEquipmentMember2022-12-310001297184us-gaap:LeaseholdImprovementsMember2022-12-310001297184us-gaap:LandMember2022-12-310001297184us-gaap:ConstructionInProgressMember2022-12-310001297184us-gaap:BuildingMember2022-12-310001297184amph:FurnitureFixturesAndVehiclesMember2022-12-310001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001297184us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001297184country:US2023-03-310001297184country:FR2023-03-310001297184country:CN2023-03-310001297184country:US2022-12-310001297184country:FR2022-12-310001297184country:CN2022-12-310001297184us-gaap:RetainedEarningsMember2023-01-012023-03-310001297184us-gaap:RetainedEarningsMember2022-01-012022-03-310001297184amph:CommitmentsToPurchaseEquipmentAndRawMaterialsMember2023-01-012023-03-310001297184amph:TermLoanDueAugust2026Memberamph:CapitalOneNationalAssociationMember2023-03-310001297184amph:MortgagePayableDueJune2027Memberamph:EastWestBankMember2023-03-310001297184amph:FrenchGovernmentLoan4DueDecember2026Memberamph:SeineNormandieWaterAgencyMember2023-03-310001297184amph:TermLoanDueAugust2026Memberamph:CapitalOneNationalAssociationMember2022-12-310001297184amph:MortgagePayableDueJune2027Memberamph:EastWestBankMember2022-12-310001297184amph:FrenchGovernmentLoan4DueDecember2026Memberamph:SeineNormandieWaterAgencyMember2022-12-310001297184amph:AmphastarPharmaceuticalsVsAstellasGileadMemberus-gaap:SettledLitigationMember2022-01-012022-03-310001297184amph:BaqsimiAcquisitionsMemberamph:SeniorSecuredRevolvingCreditFacilityMemberus-gaap:SubsequentEventMember2023-04-210001297184us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001297184us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member2023-03-310001297184us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001297184us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member2022-12-310001297184amph:EnoxaparinMember2023-01-012023-03-310001297184amph:EnoxaparinMember2022-01-012022-03-310001297184us-gaap:TrademarksMember2023-03-310001297184us-gaap:TrademarksMember2022-12-310001297184amph:NanjingHanxinPharmaceuticalTechnologyCoLtdMember2023-01-012023-03-310001297184amph:NanjingHanxinPharmaceuticalTechnologyCoLtdMember2022-01-012022-03-310001297184us-gaap:MunicipalBondsMember2023-03-310001297184amph:CorporateBondsShortTermMember2023-03-310001297184us-gaap:MunicipalBondsMember2022-12-310001297184amph:CorporateBondsShortTermMember2022-12-310001297184amph:FinishedPharmaceuticalProductsSegmentMember2023-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMember2022-12-310001297184amph:InternationalMedicationSystemsUkLimitedMemberamph:AcquiredInternationalProductRightsMember2023-01-012023-03-310001297184us-gaap:UseRightsMember2023-01-012023-03-310001297184us-gaap:PatentsMember2023-01-012023-03-310001297184amph:InternationalMedicationSystemsUkLimitedMemberamph:AcquiredInternationalProductRightsMember2022-01-012022-12-310001297184us-gaap:UseRightsMember2022-01-012022-12-310001297184us-gaap:PatentsMember2022-01-012022-12-3100012971842022-01-012022-12-310001297184amph:InternationalMedicationSystemsUkLimitedMemberamph:AcquiredInternationalProductRightsMember2023-03-310001297184us-gaap:UseRightsMember2023-03-310001297184us-gaap:PatentsMember2023-03-310001297184amph:InternationalMedicationSystemsUkLimitedMemberamph:AcquiredInternationalProductRightsMember2022-12-310001297184us-gaap:UseRightsMember2022-12-310001297184us-gaap:PatentsMember2022-12-310001297184us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2023-03-310001297184us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2023-03-310001297184us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2022-12-310001297184us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2022-12-310001297184amph:EmployeeConsultantAndDirectorsStockOptionsMember2023-03-310001297184amph:EmployeeConsultantAndDirectorsStockOptionsMember2023-01-012023-03-310001297184us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001297184us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Member2023-03-310001297184us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001297184us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Member2022-12-310001297184amph:FinishedPharmaceuticalProductsSegmentMember2023-01-012023-03-310001297184amph:ActivePharmaceuticalIngredientSegmentMember2023-01-012023-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMember2022-01-012022-03-310001297184amph:ActivePharmaceuticalIngredientSegmentMember2022-01-012022-03-310001297184amph:BaqsimiAcquisitionsMemberamph:SeniorSecuredTermLoanFacilityMemberus-gaap:SubsequentEventMember2023-04-210001297184amph:McKessonMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310001297184amph:McKessonMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310001297184amph:CardinalHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310001297184amph:CardinalHealthMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310001297184amph:AmerisourceBergenMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310001297184amph:AmerisourceBergenMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310001297184amph:McKessonMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001297184amph:CardinalHealthMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001297184amph:AmerisourceBergenMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001297184amph:McKessonMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001297184amph:CardinalHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001297184amph:AmerisourceBergenMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-310001297184us-gaap:TreasuryStockMember2023-03-310001297184us-gaap:CommonStockMember2023-03-310001297184us-gaap:TreasuryStockMember2022-12-310001297184us-gaap:CommonStockMember2022-12-310001297184us-gaap:TreasuryStockMember2022-03-310001297184us-gaap:CommonStockMember2022-03-310001297184us-gaap:TreasuryStockMember2021-12-310001297184us-gaap:CommonStockMember2021-12-310001297184us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001297184us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-03-310001297184us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001297184us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2022-12-310001297184us-gaap:FairValueMeasurementsRecurringMember2023-03-310001297184us-gaap:FairValueInputsLevel2Member2023-03-310001297184us-gaap:FairValueInputsLevel1Member2023-03-310001297184us-gaap:FairValueMeasurementsRecurringMember2022-12-310001297184us-gaap:FairValueInputsLevel2Member2022-12-310001297184us-gaap:FairValueInputsLevel1Member2022-12-310001297184amph:BaqsimiAcquisitionsMember2023-01-012023-03-310001297184us-gaap:SellingAndMarketingExpenseMember2023-01-012023-03-310001297184us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001297184us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001297184us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310001297184us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001297184us-gaap:CostOfSalesMember2023-01-012023-03-310001297184amph:EmployeeStockPurchasePlan2014Member2023-01-012023-03-310001297184us-gaap:SellingAndMarketingExpenseMember2022-01-012022-03-310001297184us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001297184us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001297184us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-03-310001297184us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001297184us-gaap:CostOfSalesMember2022-01-012022-03-310001297184amph:EmployeeStockPurchasePlan2014Member2022-01-012022-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:PrimatenemistMember2023-01-012023-03-310001297184amph:FinishedPharmaceuticalProductsSegmentMemberamph:PrimatenemistMember2022-01-012022-03-3100012971842023-05-030001297184us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001297184us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001297184us-gaap:RestrictedStockUnitsRSUMember2023-03-310001297184amph:RestrictedStockUnitsIssuedAsCompensationMember2023-01-012023-03-310001297184us-gaap:AccountsReceivableMember2023-01-012023-03-310001297184us-gaap:AccountsPayableAndAccruedLiabilitiesMember2023-01-012023-03-310001297184us-gaap:AccountsReceivableMember2022-01-012022-12-310001297184us-gaap:AccountsPayableAndAccruedLiabilitiesMember2022-01-012022-12-3100012971842022-03-3100012971842021-12-310001297184srt:MinimumMember2023-01-012023-03-310001297184srt:MaximumMember2023-01-012023-03-310001297184amph:NanjingHanxinPharmaceuticalTechnologyCoLtdMember2023-01-012023-03-310001297184us-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310001297184us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310001297184us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310001297184us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001297184us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-03-3100012971842023-01-012023-03-3100012971842022-01-012022-03-310001297184us-gaap:InterestRateSwapMember2023-01-012023-03-310001297184us-gaap:InterestRateSwapMember2022-01-012022-03-310001297184amph:BaqsimiAcquisitionsMemberus-gaap:SubsequentEventMember2023-04-200001297184amph:AssetAcquisitionEarnoutLiabilitySalesMilestoneAchievementTwoMemberamph:BaqsimiAcquisitionsMemberus-gaap:SubsequentEventMember2023-04-200001297184amph:AssetAcquisitionEarnoutLiabilitySalesMilestoneAchievementThreeMemberamph:BaqsimiAcquisitionsMemberus-gaap:SubsequentEventMember2023-04-200001297184amph:AssetAcquisitionEarnoutLiabilitySalesMilestoneAchievementOneMemberamph:BaqsimiAcquisitionsMemberus-gaap:SubsequentEventMember2023-04-200001297184amph:AssetAcquisitionContingentConsiderationSalesMilestoneAchievementThreeMemberamph:BaqsimiAcquisitionsMemberus-gaap:SubsequentEventMember2023-04-202023-04-200001297184amph:AssetAcquisitionContingentConsiderationSalesMilestoneAchievementOneMemberamph:BaqsimiAcquisitionsMemberus-gaap:SubsequentEventMember2023-04-202023-04-200001297184amph:AssetAcquisitionContingentConsiderationSalesMilestoneAchievementThreeMemberamph:BaqsimiAcquisitionsMemberus-gaap:SubsequentEventMember2023-04-012023-04-300001297184amph:AssetAcquisitionContingentConsiderationSalesMilestoneAchievementTwoMemberamph:BaqsimiAcquisitionsMemberus-gaap:SubsequentEventMember2023-04-202023-04-200001297184amph:BaqsimiAcquisitionsMemberus-gaap:SubsequentEventMember2023-04-202023-04-200001297184amph:EmployeeAndNonEmployeeStockOptionsMember2023-01-012023-03-310001297184amph:EmployeeAndNonEmployeeStockOptionsMember2022-01-012022-03-3100012971842023-03-3100012971842022-12-31iso4217:USDiso4217:USDxbrli:sharesamph:paymentamph:itemxbrli:purexbrli:sharesamph:segment

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from             to             

Commission file number 001-36509

AMPHASTAR PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

Delaware

 

33-0702205

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer
Identification No.)

11570 6th Street

 

Rancho Cucamonga, CA

 

91730

(Address of principal executive offices)

(zip code)

(909) 980-9484

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No      

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

Securities registered pursuant to Section 12(b) of the Act:

T

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

AMPH

The NASDAQ Stock Market LLC

The number of shares outstanding of the registrant’s only class of common stock as of May 3, 2023 was 48,274,042.

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

TABLE OF CONTENTS

FORM 10-Q FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023

Special Note About Forward-Looking Statements

Part I. FINANCIAL INFORMATION

PAGE

Item 1. Financial Statements (unaudited)

Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022

1

Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2023 and 2022

2

Condensed Consolidated Statements of Comprehensive Income for the Three Months Ended March 31, 2023 and 2022

3

Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2023 and 2022

4

Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2023 and 2022

5

Notes to Condensed Consolidated Financial Statements

6

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

28

Item 3. Quantitative and Qualitative Disclosure about Market Risk

36

Item 4. Controls and Procedures

36

Part II. OTHER INFORMATION

Item 1. Legal Proceedings

37

Item 1A. Risk Factors

37

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

45

Item 3. Defaults Upon Senior Securities

45

Item 4. Mine Safety Disclosures

45

Item 5. Other Information

45

Item 6. Exhibits

46

Signatures

47

Table of Contents

SPECIAL NOTE ABOUT FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, or Quarterly Report, contains “forward-looking statements” that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements relate to future events or future financial performance or condition and involve known and unknown risks, uncertainties and other factors that could cause actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by the forward-looking statements. These forward-looking statements include, but are not limited to, statements about:

our expectations regarding the sales and marketing of our products;
our expectations regarding the proposed acquisition of BAQSIMI®, including with respect to our ability to increase our revenues and derive certain benefits as a result of the acquisition of BAQSIMI®.;
our ability to successfully acquire and integrate assets, including our ability to integrate BAQSIMI®;
our expectations regarding our manufacturing and production and the integrity of our supply chain for our products, including the risks associated with our single source suppliers;
our business and operations in general, including: uncertainty regarding the magnitude, duration and geographic reach of the ongoing COVID-19 pandemic, adverse impacts of the Russia-Ukraine conflict and related macroeconomic conditions on our business, financial condition, operations, cash flows and liquidity;
our ability to successfully execute and maintain the activities and efforts related to the measures we have taken or may take in response to the COVID-19 pandemic and associated costs therewith;
our ability to attract, hire, and retain highly skilled personnel;
interruptions to our manufacturing and production as a result of natural catastrophic events or other causes beyond our control such as power disruptions or widespread disease outbreaks, such as the ongoing COVID-19 pandemic and the Russia-Ukraine conflict;
global, national and local economic and market conditions, specifically with respect to geopolitical uncertainty, including the Russia-Ukraine conflict, the ongoing COVID-19 pandemic, inflation and rising interest rates;

the timing and likelihood of U.S. Food and Drug Administration, or FDA, approvals and regulatory actions on our product candidates, manufacturing activities and product marketing activities;

our ability to advance product candidates in our platforms into successful and completed clinical trials and our subsequent ability to successfully commercialize our product candidates;
cost and delays resulting from the extensive pharmaceutical regulations to which we are subject or delays in governmental processing time due to travel and work restrictions caused by the COVID-19 pandemic;

our ability to compete in the development and marketing of our products and product candidates;
our expectations regarding the business of our Chinese subsidiary, Amphastar Nanjing Pharmaceuticals, Ltd., or ANP;

the potential for adverse application of environmental, health and safety and other laws and regulations on our operations;

our expectations for market acceptance of our new products and proprietary drug delivery technologies, as well as those of our active pharmaceutical ingredient, or API, customers;
the effects of reforms in healthcare regulations and reductions in pharmaceutical pricing, reimbursement and coverage;

our expectations in obtaining insurance coverage and adequate reimbursement for our products from third-party payers;

the amount of price concessions or exclusion of suppliers adversely affecting our business;

variations in intellectual property laws, our ability to establish and maintain intellectual property protection for our products and our ability to successfully defend our intellectual property in cases of alleged infringement;

the implementation of our business strategies, product development strategies and technology utilization;

the potential for exposure to product liability claims;

our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions, divestitures or investments, including the anticipated benefits of such acquisitions, divestitures or investments;

our ability to expand internationally;

economic and industry trends and trend analysis;

our ability to remain in compliance with laws and regulations that currently apply or become applicable to our business both in the United States and internationally;
the impact of trade tariffs, export or import restrictions, or other trade barriers;
the impact of Patient Protection and Affordable Care Act (as amended) and other legislative and regulatory healthcare reforms in the countries in which we operate including the potential for drug price controls;

Table of Contents

the impact of global and domestic tax reforms, including the Tax Cuts and Jobs Acts of 2017, or the Tax Act, as amended by the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act;

the timing for completion and the validation of the new construction at our ANP and Amphastar facilities;
the timing and extent of share buybacks; and
our financial performance expectations, including our expectations regarding our backlog, revenue, cost of revenue, gross profit or gross margin, operating expenses, including changes in research and development, sales and marketing and general and administrative expenses, and our ability to achieve and maintain future profitability.

You should read this Quarterly Report and the documents that we reference elsewhere in this Quarterly Report completely and with the understanding that our actual results may differ materially from what we expect as expressed or implied by our forward-looking statements. In light of the significant risks and uncertainties to which our forward-looking statements are subject, you should not place undue reliance on or regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all. In particular, the extent of COVID-19’s ongoing impact on our business and the impacts of the ongoing Russia-Ukraine conflict, will depend on several factors, including the severity, duration and extent of the pandemic and the conflict, all of which continue to evolve and remain uncertain at this time. We discuss many of these risks and uncertainties in greater detail in this Quarterly Report and in our Annual Report on Form 10-K for the year ended December 31, 2022, particularly in Item 1A. “Risk Factors.” These forward-looking statements represent our estimates and assumptions only as of the date of this Quarterly Report regardless of the time of delivery of this Quarterly Report, and such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this Quarterly Report.

Unless expressly indicated or the context requires otherwise, references in this Quarterly Report to “Amphastar,” “the Company,” “we,” “our,” and “us” refer to Amphastar Pharmaceuticals, Inc. and our subsidiaries.

Table of Contents

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

AMPHASTAR PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

    

March 31, 

    

December 31, 

2023

2022

(unaudited)

ASSETS

Current assets:

Cash and cash equivalents

$

176,615

$

156,098

Restricted cash

235

235

Short-term investments

16,277

19,664

Restricted short-term investments

 

2,200

 

2,200

Accounts receivable, net

 

100,638

 

88,804

Inventories

 

103,647

 

103,584

Income tax refunds and deposits

 

731

 

171

Prepaid expenses and other assets

 

7,327

 

7,563

Total current assets

 

407,670

 

378,319

Property, plant, and equipment, net

 

243,479

 

238,266

Finance lease right-of-use assets

706

753

Operating lease right-of-use assets

25,801

25,554

Investment in unconsolidated affiliate

1,758

2,414

Goodwill and intangible assets, net

 

37,179

 

37,298

Other assets

 

18,536

 

20,856

Deferred tax assets

 

38,527

 

38,527

Total assets

$

773,656

$

741,987

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable and accrued liabilities

$

88,886

$

84,242

Income taxes payable

 

11,590

 

4,571

Current portion of long-term debt

 

2,168

 

3,046

Current portion of operating lease liabilities

2,991

3,003

Total current liabilities

 

105,635

 

94,862

Long-term reserve for income tax liabilities

 

7,225

 

7,225

Long-term debt, net of current portion and unamortized debt issuance costs

 

72,872

 

72,839

Long-term operating lease liabilities, net of current portion

23,994

23,694

Deferred tax liabilities

 

178

 

144

Other long-term liabilities

 

15,175

 

14,565

Total liabilities

 

225,079

 

213,329

Commitments and contingencies

Stockholders’ equity:

Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding

 

 

Common stock: par value $0.0001; 300,000,000 shares authorized; 58,440,531 and 48,179,238 shares issued and outstanding as of March 31, 2023 and 58,110,231 and 48,112,069 shares issued and outstanding as of December 31, 2022, respectively

 

6

 

6

Additional paid-in capital

 

456,623

 

455,077

Retained earnings

 

297,755

 

271,723

Accumulated other comprehensive loss

 

(8,268)

 

(8,624)

Treasury stock

 

(197,539)

 

(189,524)

Total equity

548,577

528,658

Total liabilities and stockholders’ equity

$

773,656

$

741,987

See Accompanying Notes to Condensed Consolidated Financial Statements.

-1-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited; in thousands, except per share data)

Three Months Ended

March 31, 

    

2023

    

2022

Net revenues

$

140,022

$

120,368

Cost of revenues

 

66,182

 

64,542

Gross profit

 

73,840

 

55,826

Operating expenses:

Selling, distribution, and marketing

 

7,109

 

5,519

General and administrative

 

13,483

 

12,470

Research and development

 

19,815

 

16,223

Total operating expenses

 

40,407

 

34,212

Income from operations

 

33,433

 

21,614

Non-operating income (expenses):

Interest income

 

924

 

181

Interest expense

 

(398)

 

(355)

Other income (expenses), net

 

(390)

 

7,593

Total non-operating income (expenses), net

 

136

 

7,419

Income before income taxes

 

33,569

 

29,033

Income tax provision

 

6,752

 

4,077

Income before equity in losses of unconsolidated affiliate

26,817

24,956

Equity in losses of unconsolidated affiliate

(785)

(703)

Net income

$

26,032

$

24,253

Net income per share:

Basic

$

0.54

$

0.50

Diluted

$

0.50

$

0.47

Weighted-average shares used to compute net income per share:

Basic

 

48,000

 

48,138

Diluted

 

51,970

 

51,979

See Accompanying Notes to Condensed Consolidated Financial Statements.

-2-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited; in thousands)

Three Months Ended

March 31, 

    

2023

    

2022

Net income

$

26,032

$

24,253

Other comprehensive income (loss), net of income taxes

Foreign currency translation adjustment

 

356

 

(480)

Total other comprehensive income (loss)

 

356

 

(480)

Total comprehensive income

$

26,388

$

23,773

See Accompanying Notes to Condensed Consolidated Financial Statements.

-3-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited; in thousands, except share data)

Common Stock

Accumulated

Treasury Stock

Additional

Other

Paid-in

Retained

Comprehensive

Shares

Amount

Capital

Earnings

loss

Shares

Amount

Total

Balance as of December 31, 2022

 

58,110,231

$

6

$

455,077

$

271,723

$

(8,624)

 

(9,998,162)

$

(189,524)

$

528,658

Net income

 

 

 

 

26,032

 

 

 

 

26,032

Other comprehensive income

 

 

 

 

 

356

 

 

 

356

Purchase of treasury stock

 

 

 

 

 

 

(263,131)

(8,015)

 

(8,015)

Issuance of common stock in connection with the Company's equity plans

 

330,300

 

 

(4,565)

 

 

 

 

 

(4,565)

Share-based compensation expense

 

 

 

6,111

 

 

 

 

 

6,111

Balance as of March 31, 2023

 

58,440,531

$

6

$

456,623

$

297,755

$

(8,268)

 

(10,261,293)

$

(197,539)

$

548,577

Common Stock

Accumulated

Treasury Stock

Additional

Other

Paid-in

Retained

Comprehensive

Shares

Amount

Capital

Earnings

loss

Shares

Amount

Total

Balance as of December 31, 2021

 

56,440,202

$

6

$

422,423

$

180,337

$

(6,765)

 

(8,725,290)

$

(150,479)

$

445,522

Net income

 

 

 

 

24,253

 

 

 

 

24,253

Other comprehensive loss

 

 

 

 

 

(480)

 

 

 

(480)

Purchase of treasury stock

 

 

 

 

 

 

(51,168)

(1,229)

 

(1,229)

Issuance of treasury stock in connection with the Company's equity plans

(428)

33,231

428

Issuance of common stock in connection with the Company's equity plans

 

1,055,200

 

 

6,437

 

 

 

 

 

6,437

Share-based compensation expense

 

 

 

5,022

 

 

 

 

 

5,022

Balance as of March 31, 2022

 

57,495,402

$

6

$

433,454

$

204,590

$

(7,245)

 

(8,743,227)

$

(151,280)

$

479,525

See Accompanying Notes to Condensed Consolidated Financial Statements

-4-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited; in thousands)

Three Months Ended

March 31, 

    

2023

    

2022

Cash Flows From Operating Activities:

Net income

$

26,032

$

24,253

Reconciliation to net cash provided by operating activities:

Loss on disposal of assets

 

2

 

1

Loss (gain) on interest rate swaps and foreign currency transactions, net

195

(3,013)

Depreciation of property, plant, and equipment

 

6,252

 

5,615

Amortization of product rights, trademarks, and patents

 

241

 

352

Operating lease right-of-use asset amortization

903

828

Equity in losses of unconsolidated affiliate

785

703

Share-based compensation expense

 

6,111

 

5,022

Changes in operating assets and liabilities:

Accounts receivable, net

 

(11,796)

 

5,598

Inventories

 

268

 

(2,687)

Prepaid expenses and other assets

 

219

 

1,420

Income tax refunds, deposits, and payable, net

 

6,459

 

3,926

Operating lease liabilities

(862)

(695)

Accounts payable and accrued liabilities

 

5,573

 

9,442

Net cash provided by operating activities

 

40,382

 

50,765

Cash Flows From Investing Activities:

Purchases and construction of property, plant, and equipment

 

(9,477)

 

(6,139)

Purchase of investments

(10,574)

(5,317)

Maturity of investments

14,064

2,535

Payment of deposits and other assets

 

(346)

 

(189)

Net cash used in investing activities

 

(6,333)

 

(9,110)

Cash Flows From Financing Activities:

Proceeds from equity plans, net of withholding tax payments

 

(4,565)

 

6,437

Purchase of treasury stock

 

(8,015)

 

(1,229)

Debt issuance costs

(22)

Principal payments on long-term debt

 

(968)

 

(538)

Net cash used in financing activities

 

(13,548)

 

4,648

Effect of exchange rate changes on cash

 

16

(29)

Net increase in cash, cash equivalents, and restricted cash

 

20,517

 

46,274

Cash, cash equivalents, and restricted cash at beginning of period

 

156,333

126,588

Cash, cash equivalents, and restricted cash at end of period

$

176,850

$

172,862

Noncash Investing and Financing Activities:

Capital expenditure included in accounts payable

$

4,802

$

6,709

Operating lease right-of-use assets in exchange for operating lease liabilities

$

1,150

$

1,777

Supplemental Disclosures of Cash Flow Information:

Interest paid, net of capitalized interest

$

1,245

$

579

Income taxes paid

$

336

$

183

See Accompanying Notes to Condensed Consolidated Financial Statements.

-5-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1. General

Amphastar Pharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, hereinafter referred to as the “Company”) is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, including products with high technical barriers to market entry. Additionally, the Company sells insulin active pharmaceutical ingredient, or API, products. Most of the Company’s products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company’s insulin API products are sold to other pharmaceutical companies for use in their own products and are being used by the Company in the development of injectable finished pharmaceutical products. The Company’s inhalation product, Primatene MIST®, is primarily distributed through drug retailers.

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements of the Company for the year ended December 31, 2022 and the notes thereto as filed with the Securities and Exchange Commission, or SEC, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with United States generally accepted accounting principles, or GAAP, have been condensed or omitted from the accompanying condensed consolidated financial statements. The accompanying year-end condensed consolidated balance sheet was derived from the audited financial statements. The accompanying interim financial statements are unaudited, but reflect all adjustments which are, in the opinion of management, necessary for a fair statement of the Company’s consolidated financial position, results of operations, comprehensive income (loss), stockholders’ equity, and cash flows for the periods presented. Unless otherwise noted, all such adjustments are of a normal, recurring nature. The Company’s results of operations, comprehensive income (loss) and cash flows for the interim periods are not necessarily indicative of the results of operations and cash flows that it may achieve in future periods.

Note 2. Summary of Significant Accounting Policies

Basis of Presentation

The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries, and are prepared in accordance with GAAP. All intercompany activity has been eliminated in the preparation of the condensed consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the consolidated financial position, results of operations, and cash flows of the Company.

The Company’s subsidiaries include: (1) International Medication Systems, Limited, or IMS, (2) Armstrong Pharmaceuticals, Inc., or Armstrong, (3) Amphastar Nanjing Pharmaceuticals Inc., or ANP, (4) Amphastar France Pharmaceuticals, S.A.S., or AFP, (5) Amphastar UK Ltd., or AUK, and (6) International Medication Systems (UK) Limited, or IMS UK.

Investments in Unconsolidated Affiliate

The Company applies the equity method of accounting for investments when it has significant influence, but not controlling interest in the investee. Judgment regarding the level of influence over each equity method investment includes key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. The Company’s proportionate share of the earnings or losses resulting from these investments is reported as “Equity in losses of unconsolidated affiliate” in the accompanying consolidated statements of operations. Investments accounted for using the equity method may be reported on a lag of up to three months if financial statements of the investee are not available in sufficient time for the investor to apply the equity

-6-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

method as of the current reporting date. The determination of whether an investee’s results are recorded on a lag is made on an investment-by-investment basis.

The carrying value of equity method investments is reported as “Investment in unconsolidated affiliate” in the accompanying consolidated balance sheets. The Company’s equity method investments are reported at cost and adjusted each period for the Company’s share of the investee’s earnings or losses and dividends paid, if any.

The Company assesses equity method investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable. If the decline in value is considered to be other than temporary, the investment is written down to its estimated fair value, which establishes a new cost basis in the investment. No such impairment was identified for any of the periods presented.

Use of Estimates

The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The principal accounting estimates include: determination of allowances for credit losses, fair value of financial instruments, allowance for discounts, provision for chargebacks and rebates, provision for product returns, adjustment of inventory to its net realizable value, impairment of investments, long-lived and intangible assets and goodwill, accrual for workers’ compensation liabilities, litigation reserves, stock price volatility for share-based compensation expense, valuation allowances for deferred tax assets, and liabilities for uncertain income tax positions.

Foreign Currency

The functional currency of the Company, its domestic subsidiaries, its Chinese subsidiary ANP, and its U.K. subsidiary, AUK, is the U.S. Dollar, or USD. ANP maintains its books of record in Chinese yuan. These books are remeasured into the functional currency of USD using the current or historical exchange rates. The resulting currency remeasurement adjustments and other transactional foreign currency exchange gains and losses are reflected in the Company’s condensed consolidated statements of operations.

The Company’s French subsidiary, AFP, maintains its book of record in euros. AUK’s subsidiary, IMS UK, maintains its book of record in British pounds. These local currencies have been determined to be the subsidiaries’ respective functional currencies. Activities in the statements of operations are translated to USD using average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Equity is translated at the prevailing rate of exchange at the date of the equity transactions. Translation adjustments are reflected in stockholders’ equity and are included as a component of other accumulated comprehensive income (loss). The unrealized gains or losses of intercompany foreign currency transactions that are of a long-term investment nature are reported in other accumulated comprehensive income (loss).

The unrealized gains and losses of intercompany foreign currency transactions that are of a long-term investment nature for the three months ended March 31, 2023 and 2022 were $0.6 million gain and $0.6 million loss, respectively.

Comprehensive Income

The Company’s comprehensive income includes its foreign currency translation gains and losses as well as its share of other comprehensive income from its equity method investments.

-7-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Advertising Expense

Advertising expenses, primarily associated with Primatene MIST®, are recorded as they are incurred, except for expenses related to the development of a major commercial or media campaign, which are expensed in the period in which the commercial or campaign is first presented, and are reflected as a component of selling, distribution and marketing in the Company’s condensed consolidated statements of operations. For the three months ended March 31, 2023 and 2022, advertising expenses were $3.3 million and $2.4 million, respectively.

Financial Instruments

The carrying amounts of cash and cash equivalents, short-term investments, restricted cash and short-term investments, accounts receivable, accounts payable, accrued expenses, and short-term borrowings approximate fair value due to the short maturity of these items. The majority of the Company’s long-term obligations consist of variable rate debt, and their carrying value approximates fair value as the stated borrowing rates are comparable to rates currently offered to the Company for instruments with similar maturities. The Company at times enters into interest rate swap contracts to manage its exposure to interest rate changes and its overall cost of long-term debt. The Company’s interest rate swap contracts exchange the variable interest rates for fixed interest rates.

From time to time, the Company may enter into forward currency contracts to lock in currency exchange rates to manage its foreign currency exchange rate exposure. The Company’s interest rate swaps and forward currency contracts have not been designated as hedging instruments and, therefore are recorded at their fair values at the end of each reporting period with changes in fair value recorded in other income (expenses) on the condensed consolidated statements of operations. As of March 31, 2023, the Company did not have any unsettled forward currency contracts to purchase foreign currency. As of December 31, 2022, the Company had an unsettled forward currency contract to purchase foreign currency with a fair value of approximately $0.2 million, based on Level 2 inputs, which was recorded as a liability in the accounts payable and accrued liabilities line in the condensed consolidated balance sheets.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash, money market accounts, certificates of deposit and highly liquid investments with original maturities of three months or less.

Investments

Investments as of March 31, 2023 and December 31, 2022 consisted of certificates of deposit and investment grade corporate and municipal bonds with original maturity dates between three and fifteen months.

Restricted Cash

Restricted cash is collateral required for the Company to guarantee certain vendor payments in France. As of each of March 31, 2023 and December 31, 2022, the restricted cash balance was $0.2 million.

Restricted Short-Term Investments

Restricted short-term investments consist of certificates of deposit that are collateral for standby letters of credit to qualify for workers’ compensation self-insurance. The certificates of deposit have original maturities greater than three months, but less than one year. As of March 31, 2023 and December 31, 2022, the balance of restricted short-term investments was $2.2 million.

-8-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Deferred Income Taxes

The Company utilizes the liability method of accounting for income taxes, under which deferred taxes are determined based on the temporary differences between the financial statements and the tax basis of assets and liabilities using enacted tax rates. A valuation allowance is recorded when it is more likely than not that the deferred tax assets will not be realized.

Litigation, Commitments and Contingencies

Litigation, commitments and contingencies are accrued when management, after considering the facts and circumstances of each matter as then known to management, has determined it is probable a liability will be found to have been incurred and the amount of the loss can be reasonably estimated. When only a range of amounts is reasonably estimable and no amount within the range is more likely than another, the low end of the range is recorded. Legal fees are expensed as incurred. Due to the inherent uncertainties surrounding gain contingencies, the Company generally does not recognize potential gains until they are realized.

Recent Accounting Pronouncements

The Company does not believe that any recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying condensed consolidated financial statements.

 

Note 3. Revenue Recognition

In accordance with Accounting Standard Codification, or ASC, 606 Revenue from Contracts with Customers, revenue is recognized at the time that the Company’s customers obtain control of the promised goods.

Generally, revenue is recognized at the time of product delivery to the Company’s customers. In some cases, revenue is recognized at the time of shipment when stipulated by the terms of the sale agreements.

The consideration the Company receives in exchange for its goods or services is only recognized when it is probable that a significant reversal will not occur. The consideration to which the Company expects to be entitled includes a stated list price, less various forms of variable consideration. The Company makes significant estimates for related variable consideration at the point of sale, including chargebacks, rebates, product returns, other discounts and allowances.

The Company’s payment terms vary by types and locations of customers and the products or services offered. Payment terms differ by jurisdiction and customers, but payment is generally required in a term ranging from 30 to 75 days from date of shipment or satisfaction of the performance obligation. For certain products or services and certain customer types, the Company may require payment before products are delivered or services are rendered to customers.

Provisions for estimated chargebacks, rebates, discounts, product returns and credit losses are made at the time of sale and are analyzed and adjusted, if necessary, at each balance sheet date.

Revenues derived from contract manufacturing services are recognized when third-party products are shipped to customers.

The Company’s accounting policy is to review each agreement involving contract development and manufacturing services to determine if there are multiple revenue-generating activities that constitute more than one unit of accounting. Revenues are recognized for each unit of accounting based on revenue recognition criteria relevant to that unit. The Company does not have any revenue arrangements with multiple performance obligations.

-9-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Service revenues derived from research and development contracts are recognized over time based on progress toward satisfaction of the performance obligation. For each performance obligation satisfied over time, the Company assesses the proper method to be used for revenue recognition, either an input method to measure progress toward the satisfaction of services or an output method of determining the progress of completion of performance obligation. For the three months ended March 31, 2023 and 2022, revenues from research and development services at ANP were $0.1 million and $0.6 million, respectively.

Provision for Chargebacks and Rebates

The provision for chargebacks and rebates is a significant estimate used in the recognition of revenue. Wholesaler chargebacks relate to sales terms under which the Company agrees to reimburse wholesalers for differences between the gross sales prices at which the Company sells its products to wholesalers and the actual prices of such products that wholesalers resell under the Company’s various contractual arrangements with third parties such as hospitals and group purchasing organizations in the United States. Rebates include primarily amounts paid to retailers, payers, and providers in the United States, including those paid to state Medicaid programs, and are based on contractual arrangements or statutory requirements. The Company estimates chargebacks and rebates using the expected value method at the time of sale to wholesalers based on wholesaler inventory stocking levels, historic chargeback and rebate rates, and current contract pricing.

The provision for chargebacks and rebates is reflected as a component of net revenues. The following table is an analysis of the chargeback and rebate provision:

Three Months Ended

March 31, 

2023

2022

(in thousands)

Beginning balance

    

$

26,606

    

$

20,167

Provision for chargebacks and rebates

 

69,027

 

46,779

Credits and payments issued to third parties

 

(67,289)

 

(48,394)

Ending balance

$

28,344

$

18,552

Changes in the provision for chargebacks from period to period are primarily dependent on the Company’s sales to its wholesalers, the level of inventory held by wholesalers, and the wholesalers’ customer mix. Changes in the provision for rebates from period to period are primarily dependent on retailer’s and other indirect customers’ purchases. The approach that the Company uses to estimate chargebacks has been consistently applied for all periods presented. Variations in estimates have been historically small. The Company continually monitors the provision for chargebacks and rebates and makes adjustments when it believes that the actual chargebacks and rebates may differ from the estimates. The settlement of chargebacks and rebates generally occurs within 20 days to 60 days after the sale to wholesalers. The provision for chargebacks and rebates is recorded within accounts receivable and/or accounts payable and accrued liabilities depending on whether the Company has the right to offset with the customer.

Of the provision for chargebacks and rebates as of March 31, 2023 and December 31, 2022, $21.9 million and $20.5 million were included as a reduction to accounts receivable, net, on the condensed consolidated balance sheets, respectively. The remaining provision as of March 31, 2023 and December 31, 2022 of $6.4 million and $6.1 million, respectively, which were included in accounts payable and accrued liabilities in the condensed consolidated balance sheets.

Accrual for Product Returns

The Company offers most customers the right to return qualified excess or expired inventory for partial credit; however, API product sales are generally non-returnable. The Company’s product returns primarily consist of the returns of

-10-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

expired products from sales made in prior periods. Returned products cannot be resold. At the time product revenue is recognized, the Company records an accrual for product returns estimated using the expected value method. The accrual is based, in part, upon the historical relationship of product returns to sales and customer contract terms. The Company also assesses other factors that could affect product returns including market conditions, product obsolescence, and new competition. Although these factors do not normally give the Company’s customers the right to return products outside of the regular return policy, the Company realizes that such factors could ultimately lead to increased returns. The Company analyzes these situations on a case-by-case basis and makes adjustments to the product return reserve as appropriate.

The provision for product returns is reflected as a component of net revenues. The following table is an analysis of the product return liability:

Three Months Ended

March 31, 

2023

2022

(in thousands)

Beginning balance

    

$

19,451

    

$

21,677

Provision for product returns

 

614

 

1,192

Credits issued to third parties

 

(1,226)

 

(1,480)

Ending balance

$

18,839

$

21,389

Of the provision for product returns as of March 31, 2023 and December 31, 2022, $14.1 million and $14.9 million were included in accounts payable and accrued liabilities on the condensed consolidated balance sheets, respectively. The remaining provision as of March 31, 2023 and December 31, 2022 of $4.7 million and $4.6 million, were included in other long-term liabilities, respectively. For the three months ended March 31, 2023 and 2022, the Company’s aggregate product return rate was 1.3% and 1.6% of qualified sales, respectively.

Note 4. Net Income per Share

Basic net income per share is calculated based upon the weighted-average number of shares outstanding during the period. Diluted net income per share gives effect to all potential dilutive shares outstanding during the period, such as stock options, non-vested restricted stock units and shares issuable under the Company’s Employee Stock Purchase Plan, or ESPP.

For the three months ended March 31, 2023, options to purchase 1,403,859 shares of stock with a weighted-average exercise price of $34.96 per share were excluded from the computation of diluted net income per share because their effect would be anti-dilutive.

For the three months ended March 31, 2022, options to purchase 706,740 shares of stock with a weighted-average exercise price of $34.74 per share were excluded from the computation of diluted net income per share because their effect would be anti-dilutive.

-11-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

The following table provides the calculation of basic and diluted net income per share for each of the periods presented:

Three Months Ended

March 31, 

2023

2022

(in thousands, except per share data)

Basic and dilutive numerator:

    

    

    

    

Net income

$

26,032

$

24,253

Denominator:

Weighted-average shares outstanding — basic

 

48,000

48,138

Net effect of dilutive securities:

Incremental shares from equity awards

 

3,970

3,841

Weighted-average shares outstanding — diluted

 

51,970

 

51,979

Net income per share — basic

$

0.54

$

0.50

Net income per share — diluted

$

0.50

$

0.47

Note 5. Segment Reporting

The Company’s business is the development, manufacture, and marketing of pharmaceutical products. The Company has identified two reporting segments that each report to the Chief Operating Decision Maker, or CODM, as defined in ASC 280, Segment Reporting. The Company’s performance is assessed and resources are allocated by the CODM based on the following two reportable segments:

Finished pharmaceutical products
APIs

The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST®, glucagon, enoxaparin, naloxone, phytonadione, lidocaine, epinephrine, various critical and non-critical care drugs, as well as certain contract manufacturing and contract research revenues. The API segment manufactures and distributes recombinant human insulin API and porcine insulin API for external customers and internal product development.

-12-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Selected financial information by reporting segment is presented below:

Three Months Ended

March 31, 

2023

2022

(in thousands)

Net revenues:

    

    

    

    

Finished pharmaceutical products

$

136,010

$

116,546

API

 

4,012

3,822

Total net revenues

 

140,022

 

120,368

Gross profit (loss):

Finished pharmaceutical products

 

76,176

 

56,939

API

 

(2,336)

(1,113)

Total gross profit

 

73,840

 

55,826

Operating expenses

 

40,407

 

34,212

Income from operations

 

33,433

 

21,614

Non-operating income

 

136

 

7,419

Income before income taxes

$

33,569

$

29,033

The Company manages its business segments to the gross profit level and manages its operating and other costs on a company-wide basis. The Company does not identify total assets by segment for internal purposes, as the Company’s CODM does not assess performance, make strategic decisions, or allocate resources based on assets.

The amount of net revenues in the finished pharmaceutical product segment is presented below:

Three Months Ended

March 31, 

2023

2022

(in thousands)

Finished pharmaceutical products net revenues:

    

    

    

    

Glucagon

$

25,696

$

10,984

Primatene MIST®

23,483

24,697

Epinephrine

20,091

15,156

Lidocaine

13,646

10,590

Enoxaparin

9,867

10,124

Phytonadione

 

7,713

 

10,475

Naloxone

4,957

7,413

Other finished pharmaceutical products

 

30,557

 

27,107

Total finished pharmaceutical products net revenues

$

136,010

$

116,546

-13-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

The amount of depreciation and amortization expense included in cost of revenues, by reporting segment is presented below:

Three Months Ended

March 31, 

2023

2022

(in thousands)

Depreciation and amortization expense

    

    

    

    

Finished pharmaceutical products

$

2,446

$

1,794

API

 

953

 

948

Total depreciation and amortization expense

$

3,399

$

2,742

Net revenues and carrying values of long-lived assets by geographic regions are as follows:

Net Revenue

Long-Lived Assets

Three Months Ended

March 31, 

March 31, 

December 31, 

2023

2022

2023

2022

(in thousands)

United States

    

$

137,958

    

$

117,114

    

$

141,384

    

$

136,328

China

 

127

933

 

89,171

 

88,647

France

 

1,937

2,321

 

39,431

 

39,598

Total

$

140,022

$

120,368

$

269,986

$

264,573

Note 6. Customer and Supplier Concentration

Customer Concentrations

Three large wholesale drug distributors, AmerisourceBergen Corporation, or AmerisourceBergen, Cardinal Health, Inc., or Cardinal, and McKesson Corporation, or McKesson, are all distributors of the Company’s products, as well as suppliers of a broad range of health care products. The Company considers these three customers to be its major customers, as each individually, and these customers collectively, represented a significant percentage of the Company’s net revenue for the three months ended March 31, 2023 and 2022 and accounts receivable as of March 31, 2023 and December 31, 2022, respectively. The following table provides accounts receivable and net revenue information for these major customers:

% of Total Accounts

% of Net

Receivable

Revenue

Three Months Ended

March 31, 

December 31, 

March 31, 

    

2023

    

2022

    

2023

    

2022

    

AmerisourceBergen

 

16

%

16

%

24

%

22

%

McKesson

 

31

%

32

%

23

%

18

%

Cardinal Health

 

21

%

19

%

16

%

16

%

Supplier Concentrations

The Company depends on suppliers for raw materials, APIs, and other components that are subject to stringent FDA requirements. Some of these materials may only be available from one or a limited number of sources. Establishing additional or replacement suppliers for these materials may take a substantial period of time, as suppliers must be approved by the FDA. Furthermore, a significant portion of raw materials may only be available from foreign sources. If the Company is unable to secure, on a timely basis, sufficient quantities of the materials it depends on to manufacture

-14-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

and market its products, it could have a materially adverse effect on the Company’s business, financial condition, and results of operations.

Note 7. Fair Value Measurements

GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal or most advantageous market for the asset or liability at the measurement date (an exit price). These standards also establish a hierarchy that prioritizes observable and unobservable inputs used in measuring fair value of an asset or liability, as described below:

Level 1 – Inputs to measure fair value are based on quoted prices (unadjusted) in active markets on identical assets or liabilities;

Level 2 – Inputs to measure fair value are based on the following: a) quoted prices in active markets on similar assets or liabilities, b) quoted prices for identical or similar instruments in inactive markets, or c) observable (other than quoted prices) or collaborated observable market data used in a pricing model from which the fair value is derived; and

Level 3 – Inputs to measure fair value are unobservable and the assets or liabilities have little, if any, market activity; these inputs reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the assets or liabilities based on best information available in the circumstances.

As of March 31, 2023, cash equivalents include money market accounts and corporate and municipal bonds with original maturities of less than three months. Investments consist of certificates of deposit as well as investment-grade corporate, agency and municipal bonds with original maturity dates between three and twelve months. The certificates of deposit are carried at amortized cost in the Company’s condensed consolidated balance sheets, which approximates their fair value determined based on Level 2 inputs. The corporate, agency and municipal bonds are classified as held-to-maturity and are carried at amortized cost net of allowance for credit losses, which approximates their fair value determined based on Level 2 inputs. The restrictions on restricted cash and investments have an immaterial effect on the fair value of these financial assets.

The fair value of the Company’s financial assets and liabilities measured on a recurring basis as of March 31, 2023 and December 31, 2022, are as follows:

    

Total

    

(Level 1)

    

(Level 2)

    

(Level 3)

 

(in thousands)

 

Cash equivalents

$

123,064

$

123,064

$

$

Restricted cash

235

235

Short-term investments

4,600

4,600

Restricted short-term investments

 

2,200

 

 

2,200

 

Corporate, agency and municipal bonds

11,603

11,603

Interest rate swaps related to variable rate loans

5,084

5,084

Fair value measurement as of March 31, 2023

$

146,786

$

123,299

$

23,487

$

Cash equivalents

$

130,199

$

130,199

$

$

Restricted cash

235

235

Short-term investments

4,600

4,600

Restricted short-term investments

 

2,200

 

 

2,200

 

Corporate, agency and municipal bonds

14,931

14,931

Interest rate swaps related to variable rate loans

6,048

6,048

Fair value measurement as of December 31, 2022

$

158,213

$

130,434

$

27,779

$

-15-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

The Company does not hold any Level 3 instruments that are measured at fair value on a recurring basis.

Nonfinancial assets and liabilities are not measured at fair value on a recurring basis but are subject to fair value adjustments in certain circumstances. These items primarily include investments in unconsolidated affiliates, long-lived assets, goodwill, and intangible assets for which the fair value is determined as part of the related impairment test. As of March 31, 2023 and December 31, 2022, there were no significant adjustments to fair value for nonfinancial assets or liabilities.

The deferred compensation plan assets are valued using the cash surrender value of the life insurance policies and are not included in the table above.

Note 8. Investments

A summary of the Company’s investments that are classified as held-to-maturity are as follows:

Gross

Gross

Amortized

Unrealized

Unrealized

Fair

    

Cost

    

Gains

    

Losses

    

Value

(in thousands)

Corporate and agency bonds (due within 1 year)

$

19,101

$

$

(29)

$

19,072

Municipal bonds (due within 1 year)

878

878

Total investments as of March 31, 2023

$

19,979

$

$

(29)

$

19,950

Corporate and agency bonds (due within 1 year)

$

21,612

$

$

(60)

$

21,552

Municipal bonds (due within 1 year)

1,903

(2)

1,901

Total investments as of December 31, 2022

$

23,515

$

$

(62)

$

23,453

At each reporting period, the Company evaluates securities for impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the underlying credit quality and credit ratings of the issuers, identifying neither a significant deterioration since purchase nor any other factors that would indicate a material credit loss.

The Company measures expected credit losses on held-to-maturity investments on a collective basis. All the Company’s held-to-maturity investments were considered to be one pool. The estimate for credit losses considers historical loss information that is adjusted for current conditions and reasonable and supportable forecasts. Expected credit losses on held-to-maturity investments were not material to the condensed consolidated financial statements.

Investment in unconsolidated affiliate

The Company accounts for its share of the earnings or losses of its unconsolidated affiliate (Hanxin) with a reporting lag of three months, as the financial statements of Hanxin are not completed on a basis that is sufficient for the Company to apply the equity method on a current basis. The Company’s share of Hanxin’s losses for the three months ended March 31, 2023 and 2022 was $0.8 million and $0.7 million, respectively, which was recorded in the “Equity in losses of unconsolidated affiliate” line on the condensed consolidated statement of operations.

-16-

Table of Contents

AMPHASTAR PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 9. Goodwill and Intangible Assets

The table below shows the weighted-average life, original cost, accumulated amortization, and net book value by major intangible asset classification:

Weighted-Average

Accumulated

 

    

Life (Years)

    

Original Cost

    

Amortization

    

Net Book Value

 

(in thousands)

 

Definite-lived intangible assets

IMS (UK) international product rights

10

$

8,655

$

5,770

$

2,885

Patents

 

12

 

486

366

 

120

Land-use rights

 

39

 

2,540

766

 

1,774

Subtotal

 

11

 

11,681

 

6,902

 

4,779

Indefinite-lived intangible assets

Trademark

 

*

 

29,225

 

 

29,225

Goodwill - Finished pharmaceutical products

 

*

 

3,175

 

 

3,175

Subtotal

 

*

 

32,400

 

 

32,400

As of March 31, 2023

 

*

$

44,081

$

6,902

$

37,179

Weighted-Average

Accumulated

 

    

Life (Years)

    

Original Cost

    

Amortization

    

Net Book Value

 

(in thousands)

 

Definite-lived intangible assets

IMS (UK) international product rights

10

$

8,462

$

5,430

$

3,032

Patents

 

12

 

486

362

 

124

Land-use rights

 

39

 

2,540

749

 

1,791

Subtotal

 

11

 

11,488

 

6,541

 

4,947

Indefinite-lived intangible assets

Trademark

 

*

 

29,225

 

 

29,225

Goodwill - Finished pharmaceutical products

 

*

<